379 related articles for article (PubMed ID: 35088840)
1. Matrix metalloproteinase 10 is linked to the risk of progression to dementia of the Alzheimer's type.
Martino Adami PV; Orellana A; García P; Kleineidam L; Alarcón-Martín E; Montrreal L; Aguilera N; Espinosa A; Abdelnour C; Rosende-Roca M; Pablo Tartari J; Vargas L; Mauleón A; Esteban-De Antonio E; López-Cuevas R; Dalmasso MC; Campos Martin R; Parveen K; Andrade Fuentes VM; Amin N; Ahmad S; Ikram MA; Lewczuk P; Kornhuber J; Peters O; Frölich L; Rüther E; Wiltfang J; Tarraga L; Boada M; Maier W; de Rojas I; Cano A; Sanabria A; Alegret M; Hernández I; Marquié M; Valero S; van Duijn CM; Wagner M; Jessen F; Schneider A; Sáez Goñi ME; González Pérez A; Ruiz A; Ramírez A
Brain; 2022 Jul; 145(7):2507-2517. PubMed ID: 35088840
[TBL] [Abstract][Full Text] [Related]
2. Sex differences in Alzheimer's disease: plasma MMP-9 and markers of disease severity.
Tsiknia AA; Sundermann EE; Reas ET; Edland SD; Brewer JB; Galasko D; Banks SJ;
Alzheimers Res Ther; 2022 Nov; 14(1):160. PubMed ID: 36324151
[TBL] [Abstract][Full Text] [Related]
3. Don't forget about tau: the effects of ApoE4 genotype on Alzheimer's disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment-data from the Dementia Competence Network.
Benson GS; Bauer C; Hausner L; Couturier S; Lewczuk P; Peters O; Hüll M; Jahn H; Jessen F; Pantel J; Teipel SJ; Wagner M; Schuchhardt J; Wiltfang J; Kornhuber J; Frölich L
J Neural Transm (Vienna); 2022 Jun; 129(5-6):477-486. PubMed ID: 35061102
[TBL] [Abstract][Full Text] [Related]
4. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
[TBL] [Abstract][Full Text] [Related]
6. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
[TBL] [Abstract][Full Text] [Related]
7. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
[TBL] [Abstract][Full Text] [Related]
8. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease.
Janelidze S; Bali D; Ashton NJ; Barthélemy NR; Vanbrabant J; Stoops E; Vanmechelen E; He Y; Dolado AO; Triana-Baltzer G; Pontecorvo MJ; Zetterberg H; Kolb H; Vandijck M; Blennow K; Bateman RJ; Hansson O
Brain; 2023 Apr; 146(4):1592-1601. PubMed ID: 36087307
[TBL] [Abstract][Full Text] [Related]
9. CSF ferritin in the clinicopathological progression of Alzheimer's disease and associations with APOE and inflammation biomarkers.
Ayton S; Janelidze S; Kalinowski P; Palmqvist S; Belaidi AA; Stomrud E; Roberts A; Roberts B; Hansson O; Bush AI
J Neurol Neurosurg Psychiatry; 2023 Mar; 94(3):211-219. PubMed ID: 36357168
[TBL] [Abstract][Full Text] [Related]
10. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J
Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593
[TBL] [Abstract][Full Text] [Related]
11. Influence of plasma matrix metalloproteinase levels on longitudinal changes in Alzheimer's disease (AD) biomarkers and cognitive function in patients with mild cognitive impairment due to AD registered in the Alzheimer's Disease Neuroimaging Initiative database.
Abe K; Chiba Y; Hattori S; Yoshimi A; Asami T; Katsuse O; Suda A; Hishimoto A;
J Neurol Sci; 2020 Sep; 416():116989. PubMed ID: 32603972
[TBL] [Abstract][Full Text] [Related]
12. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
[TBL] [Abstract][Full Text] [Related]
13. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
14. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression.
Clark C; Lewczuk P; Kornhuber J; Richiardi J; Maréchal B; Karikari TK; Blennow K; Zetterberg H; Popp J
Alzheimers Res Ther; 2021 Mar; 13(1):65. PubMed ID: 33766131
[TBL] [Abstract][Full Text] [Related]
15. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.
Wang H; Stewart T; Toledo JB; Ginghina C; Tang L; Atik A; Aro P; Shaw LM; Trojanowski JQ; Galasko DR; Edland S; Jensen PH; Shi M; Zhang J;
J Alzheimers Dis; 2018; 61(4):1541-1553. PubMed ID: 29376878
[TBL] [Abstract][Full Text] [Related]
16. Amyloid pathology but not APOE ε4 status is permissive for tau-related hippocampal dysfunction.
Düzel E; Ziegler G; Berron D; Maass A; Schütze H; Cardenas-Blanco A; Glanz W; Metzger C; Dobisch L; Reuter M; Spottke A; Brosseron F; Fliessbach K; Heneka MT; Laske C; Peters O; Priller J; Spruth EJ; Ramirez A; Speck O; Schneider A; Teipel S; Kilimann I; Jens W; Schott BH; Preis L; Gref D; Maier F; Munk MH; Roy N; Ballarini T; Yakupov R; Haynes JD; Dechent P; Scheffler K; Wagner M; Jessen F
Brain; 2022 May; 145(4):1473-1485. PubMed ID: 35352105
[TBL] [Abstract][Full Text] [Related]
17. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population.
Xie Q; Ni M; Gao F; Dai LB; Lv XY; Zhang YF; Shi Q; Zhu XX; Xie JK; Shen Y; Wang SC
ACS Chem Neurosci; 2022 May; 13(10):1558-1565. PubMed ID: 35476397
[TBL] [Abstract][Full Text] [Related]
18. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
[TBL] [Abstract][Full Text] [Related]
19. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
[TBL] [Abstract][Full Text] [Related]
20. Predictive Accuracy of Blood-Derived Biomarkers for Amyloid-β Brain Deposition Along with the Alzheimer's Disease Continuum: A Systematic Review.
Cianflone A; Coppola L; Mirabelli P; Salvatore M
J Alzheimers Dis; 2021; 84(1):393-407. PubMed ID: 34542072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
